Fenwick Represents Star Therapeutics in its Pending Sale of Vega Therapeutics to Incyte

Fenwick represented Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies, in the pending sale of its whole owned subsidiary, Vega Therapeutics, to Incyte, a global biopharmaceutical company.

Under the terms of the agreement, Star will receive up to $2.0 billion in cash, including $1.25 billion up front and up to $750 million in additional payments upon the achievement of sales milestones. The proposed acquisition would add latarcibart (VGA039), a novel monoclonal antibody, to Incyte’s hematology portfolio. More information can be obtained from the parties’ announcement.

The Fenwick transaction team includes corporate partners Matt Rossiter, Doug Cogen, David Michaels and Victoria Lupu and associates Rob O’Connor and Ben See; technology transactions partner Jake Handy and associates Kehl Sink and Rob Ferrari; executive compensation partner Marshall Mort and associate Jonathan Stephenson; antitrust partner Tom Ensign and counsel Meredith Mommers; tax partner Will Skinner and associate Kris Hatch; and privacy counsel Sari Ratican and associate Natalie Kim.